Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

@inproceedings{Jacobsen2016LiraglutideIT,
  title={Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics},
  author={Lisbeth Vesterg{\aa}rd Jacobsen and A. K. Flint and Anette Kristensen Olsen and Steen Hvass Ingwersen},
  booktitle={Clinical pharmacokinetics},
  year={2016}
}
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutaneous injection once daily. The pharmacokinetic properties of liraglutide enable 24-h exposure coverage, a requirement for 24-h glycaemic control with once-daily dosing. The mechanism of protraction relates to slowed release from the injection site… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 81 REFERENCES

Potential of liraglutide in the treatment of patients with type 2 diabetes

  • Vascular health and risk management
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…